Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00190723 · ClinicalTrials.gov registry record · Phase 2
A Study of LY317615 in Patients With Brain Tumors
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00190723 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 120 participants.
The verdict
NCT00190723, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.
Interventions
- DRUG Enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00190723
The ClinicalTrials.gov registry entry for NCT00190723 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enzastaurin is the first listed.
NCT00190723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00190723 about?
NCT00190723 is a clinical study titled "A Study of LY317615 in Patients With Brain Tumors". 1. The safety of LY317615 and any side effects that might be associated with the drug. 2. Whether LY317615, can help patients with brain tumors.
What is the current status of trial NCT00190723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2002-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00190723?
The interventions under investigation include: Enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00190723?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.